Clinical experience with exenatide in predominantly Asian and Pacific Islander patients with type 2 diabetes

Nalurporn Chokrungvaranon; Teera Chentanez; Richard Arakaki
December 2007
Endocrine (1355008X);Dec2007, Vol. 32 Issue 3, p311
Academic Journal
Abstract  Exenatide is a new injectable medication for the treatment of hyperglycemia in type 2 diabetes. Due to limited information of exenatide use in Asians and Pacific Islanders (API), we retrospectively reviewed API patients’ responses to exenatide treatment and compared the efficacy and safety of treatment to Caucasian patients. A total of 92 patients (70 API, 21 Caucasians, and 1 Hispanic) with type 2 diabetes were treated with exenatide. In all patients, there was a significant decrease in A1c level, BMI, and weight after 6 months of exenatide treatment (A1c from 8.63 ± 1.46 to 8.23 ± 1.46; P = 0.03, BMI from 34.54 ± 7.07 to 32.14 ± 6.41; P P N = 51). However, differences in mean change of A1c level, BMI, and weight between API and Caucasian patients were not observed at 3 and 6 months of treatment. Side effects and discontinuation of exenatide treatment between API and Caucasian patients were similar. In conclusion, exenatide is an effective anti-hyperglycemic agent in API patients with responses similar to that observed for Caucasian patients.


Related Articles

  • Are you a diabetes consultant, counselor or coach? Austin, Mary M. // Endocrine Today;3/10/2008, Vol. 6 Issue 4, p29 

    The article differentiates the roles of diabetes consultants, diabetes counselors and diabetes coaches. According to the author, a consultant is an expert in the field who helps patients know what the problem or the diagnosis is and tells them how to fix it. A counselor answers the "why"...

  • Review: interventions focusing on patient behaviours in provider patient interactions improve diabetes outcomes. Mantori, Victor M. // Evidence Based Medicine;Mar/Apr2004, Vol. 9 Issue 2, p60 

    The article informs that interventions targeting patient behavior seem to have better results than those targeting clinician behavior in the patients with diabetes. Healthcare professionals in some practices have made efforts to redesign their delivery of diabetes care to include effective...

  • Strategies to Improve Diabetes Care. Bodenheimer, Thomas // American Family Physician;10/15/2003, Vol. 68 Issue 8, p1500 

    Discusses strategies to improve diabetes care. Foundation of the Chronic Care Model registry; Establishment of a patient self-management training; Benefits of physician feedback.

  • Half stroke victims glucose intolerant. Baines, Emma // GP: General Practitioner;2/11/2005, p3 

    This article informs that most stroke patients could benefit from blood glucose lowering therapy. Researchers found that more than half of stroke patients, who had not previously been diagnosed as having diabetes, had abnormal glucose tolerance. They performed an oral glucose challenge on 98...

  • Implementation salvage experiences from the Melbourne diabetes prevention study. Dunbar, James; Hernan, Andrea; Janus, Edward; Davis-Lameloise, Nathalie; Asproloupos, Dino; O'Reilly, Sharleen; Timoshanko, Amy; Stewart, Elizabeth; Bennett, Catherine M; Johnson, Greg; Carter, Rob // BMC Public Health;2012, Vol. 12 Issue 1, p1 

    Background: Many public health interventions based on apparently sound evidence from randomised controlled trials encounter difficulties when being scaled up within health systems. Even under the best of circumstances, implementation is exceedingly difficult. In this paper we will describe the...

  • Calibration of HbA1c and its measurement in the presence of variant haemoglobins: report on questionnaire to manufacturers. Manley, S E; Round, R A; Smith, J M // Annals of Clinical Biochemistry;Mar2006, Vol. 43 Issue 2, p135 

    Aims: To review 'Diabetes Control and Complications Trial (DCCT)-aligned' HbA1c reporting in UK, use of individual/network equations relating IFCC calibration to 'DCCT alignment', and whether HbA1c in the presence of variant haemoglobins is, according to manufacturers, suitable for current,...

  • Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach. Cryer, Dennis R.; Nicholas, Savian P.; Henry, David H.; Mills, Donna J.; Stadel, Bruce V. // Diabetes Care;Mar2005, Vol. 28 Issue 3, p539 

    OBJECTIVE -- Metformin was approved by the Food and Drug Administration in 1995 subject to the conduct of a randomized trial to evaluate the risk of lactic acidosis or other serious adverse events (SAEs) with this agent, under usual care conditions. RESEARCH DESIGN AND METHODS -- The Comparative...

  • The myth of the metabolic syndrome. Gale, Edwin A. M. // Diabetologia;Sep2005, Vol. 48 Issue 9, p1679 

    Explores the etiology and pathology of diabetes. Disorders marked by excessive urination and persistent thirst; Changes in blood glucose levels and blood pressure; Risk of diabetes for arterial disease, obesity, resistance to the actions of insulin and high blood pressure.

  • Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Berk-Planken, Ingrid; De Konig, Inge; Stolk, Ronald; Jansen, Hans; Hoogerbrugge, Nicoline // Diabetes Care;Jul2002, Vol. 25 Issue 7, p1250 

    Presents a letter to the editor regarding how verbal memory and complex information processing are affected in patients with diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics